Ascendis Pharma A/S
ASND
株式のランク
#1549
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
株価
$225.96
時価総額
$14.09B
変化（1日）
0.32%
変化（1年）
7.34%
国
DK
取引 Ascendis Pharma A/S (ASND)
カテゴリー
Healthcare
Ascendis Pharma A/S（ASND）のEPS
June 2026 時点のEPS TTM: $14.35
Ascendis Pharma A/Sの最新の財務報告と株価によると、同社の現在のEPS（TTM）は$14.35です。2024年末には、EPSは$-6.79で、2023年のEPS$-9.45と減少でした。
Ascendis Pharma A/SのEPS履歴（2012から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $14.35 | -437.71% |
| 2025 | $-4.25 | -37.49% |
| 2024 | $-6.79 | -28.11% |
| 2023 | $-9.45 | -15.28% |
| 2022 | $-11.16 | 40.15% |
| 2021 | $-7.96 | -21.06% |
| 2020 | $-10.08 | 91.63% |
| 2019 | $-5.26 | 44.45% |
| 2018 | $-3.64 | -17.50% |
| 2017 | $-4.42 | 62.66% |
| 2016 | $-2.71 | 79.86% |
| 2015 | $-1.51 | 118.83% |
| 2014 | $-0.69 | -231.97% |
| 2013 | $0.52 | 230.13% |
| 2012 | $0.16 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | 20.68% |
US
|
|
| $-7.98 | -155.60% |
US
|
|
| $-5.29 | -136.86% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 93.28% |
NL
|
